Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis

Amanda Kirane, Kathleen F. Ludwig, Noah Sorrelle, Gry Haaland, Tone Sandal, Renate Ranaweera, Jason E. Toombs, Miao Wang, Sean P. Dineen, David Micklem, Michael T. Dellinger, James B. Lorens, Rolf A. Brekken

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Repurposing "old" drugs can facilitate rapid clinical translation but necessitates novel mechanistic insight. Warfarin, a vitamin K "antagonist" used clinically for the prevention of thrombosis for more than 50 years, has been shown to have anticancer effects. We hypothesized that the molecular mechanism underlying its antitumor activity is unrelated to its effect on coagulation, but is due to inhibition of the Axl receptor tyrosine kinase on tumor cells. Activation of Axl by its ligand Gas6, a vitamin K-dependent protein, is inhibited at doses of warfarin that do not affect coagulation. Here, we show that inhibiting Gas6-dependent Axl activation with low-dose warfarin, or with other tumor-specific Axl-targeting agents, blocks the progression and spread of pancreatic cancer. Warfarin also inhibited Axl-dependent tumor cell migration, invasiveness, and proliferation while increasing apoptosis and sensitivity to chemotherapy. We conclude that Gas6-induced Axl signaling is a critical driver of pancreatic cancer progression and its inhibition with low-dose warfarin or other Axl-targeting agents may improve outcome in patients with Axl-expressing tumors.

Original languageEnglish (US)
Pages (from-to)3699-3705
Number of pages7
JournalCancer Research
Volume75
Issue number18
DOIs
StatePublished - Sep 15 2015

Fingerprint

Warfarin
Pancreatic Neoplasms
Neoplasm Metastasis
Vitamin K
Neoplasms
Drug Repositioning
Cell Movement
Thrombosis
Cell Proliferation
Apoptosis
Ligands
Drug Therapy
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. / Kirane, Amanda; Ludwig, Kathleen F.; Sorrelle, Noah; Haaland, Gry; Sandal, Tone; Ranaweera, Renate; Toombs, Jason E.; Wang, Miao; Dineen, Sean P.; Micklem, David; Dellinger, Michael T.; Lorens, James B.; Brekken, Rolf A.

In: Cancer Research, Vol. 75, No. 18, 15.09.2015, p. 3699-3705.

Research output: Contribution to journalArticle

Kirane, A, Ludwig, KF, Sorrelle, N, Haaland, G, Sandal, T, Ranaweera, R, Toombs, JE, Wang, M, Dineen, SP, Micklem, D, Dellinger, MT, Lorens, JB & Brekken, RA 2015, 'Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis', Cancer Research, vol. 75, no. 18, pp. 3699-3705. https://doi.org/10.1158/0008-5472.CAN-14-2887-T
Kirane, Amanda ; Ludwig, Kathleen F. ; Sorrelle, Noah ; Haaland, Gry ; Sandal, Tone ; Ranaweera, Renate ; Toombs, Jason E. ; Wang, Miao ; Dineen, Sean P. ; Micklem, David ; Dellinger, Michael T. ; Lorens, James B. ; Brekken, Rolf A. / Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. In: Cancer Research. 2015 ; Vol. 75, No. 18. pp. 3699-3705.
@article{3753419ed8934acea4ca5d2985aa6eb7,
title = "Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis",
abstract = "Repurposing {"}old{"} drugs can facilitate rapid clinical translation but necessitates novel mechanistic insight. Warfarin, a vitamin K {"}antagonist{"} used clinically for the prevention of thrombosis for more than 50 years, has been shown to have anticancer effects. We hypothesized that the molecular mechanism underlying its antitumor activity is unrelated to its effect on coagulation, but is due to inhibition of the Axl receptor tyrosine kinase on tumor cells. Activation of Axl by its ligand Gas6, a vitamin K-dependent protein, is inhibited at doses of warfarin that do not affect coagulation. Here, we show that inhibiting Gas6-dependent Axl activation with low-dose warfarin, or with other tumor-specific Axl-targeting agents, blocks the progression and spread of pancreatic cancer. Warfarin also inhibited Axl-dependent tumor cell migration, invasiveness, and proliferation while increasing apoptosis and sensitivity to chemotherapy. We conclude that Gas6-induced Axl signaling is a critical driver of pancreatic cancer progression and its inhibition with low-dose warfarin or other Axl-targeting agents may improve outcome in patients with Axl-expressing tumors.",
author = "Amanda Kirane and Ludwig, {Kathleen F.} and Noah Sorrelle and Gry Haaland and Tone Sandal and Renate Ranaweera and Toombs, {Jason E.} and Miao Wang and Dineen, {Sean P.} and David Micklem and Dellinger, {Michael T.} and Lorens, {James B.} and Brekken, {Rolf A.}",
year = "2015",
month = "9",
day = "15",
doi = "10.1158/0008-5472.CAN-14-2887-T",
language = "English (US)",
volume = "75",
pages = "3699--3705",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis

AU - Kirane, Amanda

AU - Ludwig, Kathleen F.

AU - Sorrelle, Noah

AU - Haaland, Gry

AU - Sandal, Tone

AU - Ranaweera, Renate

AU - Toombs, Jason E.

AU - Wang, Miao

AU - Dineen, Sean P.

AU - Micklem, David

AU - Dellinger, Michael T.

AU - Lorens, James B.

AU - Brekken, Rolf A.

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Repurposing "old" drugs can facilitate rapid clinical translation but necessitates novel mechanistic insight. Warfarin, a vitamin K "antagonist" used clinically for the prevention of thrombosis for more than 50 years, has been shown to have anticancer effects. We hypothesized that the molecular mechanism underlying its antitumor activity is unrelated to its effect on coagulation, but is due to inhibition of the Axl receptor tyrosine kinase on tumor cells. Activation of Axl by its ligand Gas6, a vitamin K-dependent protein, is inhibited at doses of warfarin that do not affect coagulation. Here, we show that inhibiting Gas6-dependent Axl activation with low-dose warfarin, or with other tumor-specific Axl-targeting agents, blocks the progression and spread of pancreatic cancer. Warfarin also inhibited Axl-dependent tumor cell migration, invasiveness, and proliferation while increasing apoptosis and sensitivity to chemotherapy. We conclude that Gas6-induced Axl signaling is a critical driver of pancreatic cancer progression and its inhibition with low-dose warfarin or other Axl-targeting agents may improve outcome in patients with Axl-expressing tumors.

AB - Repurposing "old" drugs can facilitate rapid clinical translation but necessitates novel mechanistic insight. Warfarin, a vitamin K "antagonist" used clinically for the prevention of thrombosis for more than 50 years, has been shown to have anticancer effects. We hypothesized that the molecular mechanism underlying its antitumor activity is unrelated to its effect on coagulation, but is due to inhibition of the Axl receptor tyrosine kinase on tumor cells. Activation of Axl by its ligand Gas6, a vitamin K-dependent protein, is inhibited at doses of warfarin that do not affect coagulation. Here, we show that inhibiting Gas6-dependent Axl activation with low-dose warfarin, or with other tumor-specific Axl-targeting agents, blocks the progression and spread of pancreatic cancer. Warfarin also inhibited Axl-dependent tumor cell migration, invasiveness, and proliferation while increasing apoptosis and sensitivity to chemotherapy. We conclude that Gas6-induced Axl signaling is a critical driver of pancreatic cancer progression and its inhibition with low-dose warfarin or other Axl-targeting agents may improve outcome in patients with Axl-expressing tumors.

UR - http://www.scopus.com/inward/record.url?scp=84942940565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942940565&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-2887-T

DO - 10.1158/0008-5472.CAN-14-2887-T

M3 - Article

C2 - 26206560

AN - SCOPUS:84942940565

VL - 75

SP - 3699

EP - 3705

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 18

ER -